ISPH Stock Overview
Operates as a pharmaceutical distributor in Egypt. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 4/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Ibnsina Pharma Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ج.م6.70 |
| 52 Week High | ج.م7.30 |
| 52 Week Low | ج.م2.14 |
| Beta | 0.45 |
| 1 Month Change | 21.60% |
| 3 Month Change | 81.08% |
| 1 Year Change | 116.13% |
| 3 Year Change | 95.42% |
| 5 Year Change | -1.92% |
| Change since IPO | 54.43% |
Recent News & Updates
Recent updates
Shareholder Returns
| ISPH | EG Healthcare | EG Market | |
|---|---|---|---|
| 7D | 7.5% | 0.8% | -1.5% |
| 1Y | 116.1% | 70.2% | 27.5% |
Return vs Industry: ISPH exceeded the EG Healthcare industry which returned 68.4% over the past year.
Return vs Market: ISPH exceeded the EG Market which returned 25.9% over the past year.
Price Volatility
| ISPH volatility | |
|---|---|
| ISPH Average Weekly Movement | 9.1% |
| Healthcare Industry Average Movement | 6.7% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in EG Market | 9.0% |
| 10% least volatile stocks in EG Market | 3.3% |
Stable Share Price: ISPH's share price has been volatile over the past 3 months compared to the EG market.
Volatility Over Time: ISPH's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of EG stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | n/a | Mohamed Mohsen Mahgoub | www.ibnsina-pharma.com |
Ibnsina Pharma operates as a pharmaceutical distributor in Egypt. The company offers pharmaceutical and cosmetics products to private and public-sector customers, including retail chains, independent pharmacies, wholesalers, and hospitals and healthcare institutions. It also provides warehousing and logistic services for its suppliers; marketing solutions; importation and packaging services; and market research and analysis services.
Ibnsina Pharma Fundamentals Summary
| ISPH fundamental statistics | |
|---|---|
| Market cap | ج.م6.75b |
| Earnings (TTM) | ج.م361.37m |
| Revenue (TTM) | ج.م48.55b |
18.7x
P/E Ratio0.1x
P/S RatioIs ISPH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ISPH income statement (TTM) | |
|---|---|
| Revenue | ج.م48.55b |
| Cost of Revenue | ج.م44.88b |
| Gross Profit | ج.م3.66b |
| Other Expenses | ج.م3.30b |
| Earnings | ج.م361.37m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.36 |
| Gross Margin | 7.55% |
| Net Profit Margin | 0.74% |
| Debt/Equity Ratio | 860.9% |
How did ISPH perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/19 09:38 |
| End of Day Share Price | 2024/12/19 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Ibnsina Pharma is covered by 9 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Neveen Ghonima | Beltone Financial |
| Aly Adel | Beltone Financial |
| Alia El Mehelmy | CI Capital Research |